Rybrevant Faspro (Amivantamab And Hyaluronidase-Lpuj Drug Interactions
Rybrevant Faspro (Amivantamab And Hyaluronidase-Lpuj (Human Recombinant)) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rybrevant Faspro. Always confirm against the full prescribing information.
100 interactions
Acetylsalicylic acid
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid.
Level 1 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Amivantamab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Amivantamab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amivantamab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Amivantamab.
Level 2 evidence
Amitriptyline
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Amitriptyline.
Level 1 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Amivantamab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Ansuvimab is combined with Amivantamab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Amivantamab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Amivantamab.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amivantamab.
Level 2 evidence
Aripiprazole
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aripiprazole.
Level 1 evidence
Enter your NPI to unlock 8 major interactions for Rybrevant Faspro
Rybrevant Faspro (Amivantamab And Hyaluronidase-Lpuj (Human Recombinant)) has 262 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rybrevant Faspro (Amivantamab And Hyaluronidase-Lpuj (Human Recombinant)) has 23 major, 1 moderate, and 238 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rybrevant Faspro. Always confirm against the full prescribing information.